Learn More
PURPOSE The AVAGAST study showed that adding bevacizumab to chemotherapy in patients with advanced gastric cancer improves progression-free survival and tumor response rate but not overall survival. To examine the hypothesis that angiogenic markers may have predictive value for bevacizumab efficacy in gastric cancer, AVAGAST included a prospective,(More)
This paper addresses the problem of identifying differentially regulated genes in microarray experiments. We have developed a new model based on a solid approach for estimating the gene variance. We show that the empirical gene variance distribution is adequately modelled by a mixture of gamma distribution. We then derive a new test and compute p-value and(More)
BACKGROUND Identification of appropriate markers for predicting clinical benefit with erlotinib in non-small-cell lung cancer (NSCLC) may be able to guide patient selection for treatment. This open-label, multicentre, phase II trial aimed to identify genes with potential use as biomarkers for clinical benefit from erlotinib therapy. METHODS Adults with(More)
BACKGROUND No biomarkers that could guide patient selection for treatment with the anti-VEGF monoclonal antibody bevacizumab have been identified. We assessed whether genetic variants in the VEGF pathway could act as biomarkers for bevacizumab treatment outcome. METHODS We investigated DNA from white patients from two phase 3 randomised studies. In AViTA,(More)
MOTIVATION Identifying differentially regulated genes in experiments comparing two experimental conditions is often a key step in the microarray data analysis process. Many different approaches and methodological developments have been put forward, yet the question remains open. RESULTS Varmixt is a powerful and efficient novel methodology for this task.(More)
OBJECTIVE The purpose of this work was to determine the pattern of genes regulated by peroxisome proliferator-activated receptor (PPAR) gamma coactivator 1 alpha (PGC-1 alpha) in human adipocytes and the involvement of PPARalpha and PPARgamma in PGC-1 alpha transcriptional action. RESEARCH DESIGN AND METHODS Primary cultures of human adipocytes were(More)
AIM Imgatuzumab (GA201) is a novel anti-epidermal growth factor receptor (anti-EGFR) antibody glycoengineered for enhanced antibody-dependent cell-mediated cytotoxicity (ADCC). We investigated the efficacy of imgatuzumab in patients with EGFR-positive, KRAS-mutant advanced colorectal cancer. METHODS Patients received single-agent imgatuzumab (1400mg on(More)
There are currently no validated biomarkers predicting bevacizumab treatment outcome or toxicity. We combined biomarker data from six phase III trials of bevacizumab to assess whether genetic variation in vascular endothelial growth factor-A (VEGF-A) pathway or hypertension-related genes are associated with bevacizumab-induced hypertension. Germline DNA was(More)
7584 Background: R1507 is a monoclonal antibody which specifically inhibits IGF-IR. NO21160 was a randomized, placebo controlled phase II trial of two doses and schedules of R1507 + erlotinib as second/third-line therapy for advanced non-small cell lung cancer. The primary endpoint, comparison of PFS rate at 12 weeks, was not met (HR=0.99 for 16 mg q3W and(More)
Biomarkers play an increasingly important role in many aspects of pharmaceutical discovery and development, including personalized medicine and the assessment of safety data, with heavy reliance being placed on their delivery. Statisticians have a fundamental role to play in ensuring that biomarkers and the data they generate are used appropriately and to(More)